[{"address1": "210 East Grand Avenue", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 457 2700", "website": "https://www.allogene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 232, "companyOfficers": [{"maxAge": 1, "name": "Dr. Arie S. Belldegrun F.A.C.S., M.D.", "age": 75, "title": "Co-Founder & Executive Chairman", "yearBorn": 1949, "fiscalYear": 2023, "totalPay": 649097, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David D. Chang M.D., Ph.D.", "age": 64, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 994595, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joshua A. Kazam", "age": 47, "title": "Co-Founder & Director", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 260500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy L. Moore Ph.D.", "age": 63, "title": "Executive VP & Chief Technical Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 554354, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zachary J. Roberts M.D., Ph.D.", "age": 46, "title": "Executive VP of Research & Development and Chief Medical Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 747390, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Geoffrey M. Parker", "age": 59, "title": "Executive VP & CFO", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Annie  Yoshiyama", "age": 40, "title": "Senior VP, Corporate Controller & Principal Accounting Officer", "yearBorn": 1984, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Earl M. Douglas Esq.", "age": 61, "title": "Senior VP, General Counsel, Compliance Officer & Corporate Secretary", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan R. Lundeen", "age": 58, "title": "Chief People Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Cassiano", "title": "Executive VP, Chief Corporate Affairs & Brand Strategy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 10, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.41, "open": 1.55, "dayLow": 1.54, "dayHigh": 2.105, "regularMarketPreviousClose": 1.41, "regularMarketOpen": 1.55, "regularMarketDayLow": 1.54, "regularMarketDayHigh": 2.105, "beta": 0.828, "forwardPE": -1.5329816, "volume": 42511643, "regularMarketVolume": 42511643, "averageVolume": 3381251, "averageVolume10days": 6719690, "averageDailyVolume10Day": 6719690, "bid": 2.0, "ask": 2.09, "bidSize": 200, "askSize": 300, "marketCap": 427730880, "fiftyTwoWeekLow": 1.32, "fiftyTwoWeekHigh": 5.78, "priceToSalesTrailing12Months": 9947.2295, "fiftyDayAverage": 1.9456, "twoHundredDayAverage": 2.46695, "currency": "USD", "enterpriseValue": 228691072, "floatShares": 148837831, "sharesOutstanding": 209672000, "sharesShort": 32048327, "sharesShortPriorMonth": 30906822, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.1529, "heldPercentInsiders": 0.18070999, "heldPercentInstitutions": 0.80716, "shortRatio": 11.7, "shortPercentOfFloat": 0.2149, "impliedSharesOutstanding": 209672000, "bookValue": 2.214, "priceToBook": 0.9214092, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -283428992, "trailingEps": -1.55, "forwardEps": -1.39, "enterpriseToRevenue": 5318.397, "enterpriseToEbitda": -0.897, "52WeekChange": -0.5612903, "SandP52WeekChange": 0.22894537, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ALLO", "underlyingSymbol": "ALLO", "shortName": "Allogene Therapeutics, Inc.", "longName": "Allogene Therapeutics, Inc.", "firstTradeDateEpochUtc": 1539264600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "074a6d28-e148-3d16-a323-524e6da42340", "messageBoardId": "finmb_558022022", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.04, "targetHighPrice": 14.0, "targetLowPrice": 3.0, "targetMeanPrice": 9.22727, "targetMedianPrice": 9.0, "recommendationMean": 1.82353, "recommendationKey": "buy", "numberOfAnalystOpinions": 11, "totalCash": 291564000, "totalCashPerShare": 1.391, "ebitda": -254972992, "totalDebt": 92524000, "quickRatio": 9.038, "currentRatio": 9.346, "totalRevenue": 43000, "debtToEquity": 19.951, "returnOnAssets": -0.25823, "returnOnEquity": -0.54148996, "grossProfits": -201944992, "freeCashflow": -111507504, "operatingCashflow": -217308992, "operatingMargins": -6252.465, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-17"}]